CAPLIN POINT LABORATORIES LIMITED Financials Caplin Point Laboratories Limited NSE India S.E.
Equities
CAPLIPOINT
INE475E01026
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,315 INR | -1.96% |
|
+0.70% | -3.04% |
| 05-16 | Caplin Point Laboratories to Seek Acquisitions | CI |
| 05-16 | Transcript : Caplin Point Laboratories Limited, Q4 2024 Earnings Call, May 16, 2024 |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 30,430 | 21,358 | 30,571 | 51,529 | 45,291 | 101,648 | - | - |
| Enterprise Value (EV) 1 | 30,430 | 21,358 | 30,571 | 51,529 | 45,291 | 100,038 | 101,648 | 101,648 |
| P/E ratio | - | 10 x | 12.7 x | 17.3 x | 12.1 x | 22 x | 20.8 x | 18.1 x |
| Yield | - | 0.89% | 0.74% | 0.29% | 0.34% | 0.24% | 0.25% | 0.27% |
| Capitalization / Revenue | 4.69 x | 2.47 x | 2.88 x | 4.06 x | 3.09 x | 5.91 x | 5.26 x | 4.65 x |
| EV / Revenue | 4.69 x | 2.47 x | 2.88 x | 4.06 x | 3.09 x | 5.91 x | 5.26 x | 4.65 x |
| EV / EBITDA | 12.2 x | 7.09 x | 9.3 x | 13.1 x | 10.3 x | 18.1 x | 16.1 x | 14.4 x |
| EV / FCF | - | -66.6 x | 15.7 x | 21 x | 58.1 x | 47.8 x | 31 x | 25.5 x |
| FCF Yield | - | -1.5% | 6.39% | 4.77% | 1.72% | 2.09% | 3.22% | 3.92% |
| Price to Book | 4.83 x | 2.27 x | 2.58 x | 3.47 x | 2.41 x | 4.42 x | 3.3 x | 2.93 x |
| Nbr of stocks (in thousands) | 75,630 | 75,643 | 75,643 | 75,789 | 75,903 | 75,942 | - | - |
| Reference price 2 | 402.4 | 282.4 | 404.2 | 679.9 | 596.7 | 1,338 | 1,338 | 1,338 |
| Announcement Date | 19-05-22 | 20-06-18 | 21-05-06 | 22-05-12 | 23-05-27 | 24-05-16 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6,487 | 8,632 | 10,613 | 12,694 | 14,667 | 16,941 | 19,332 | 21,852 |
| EBITDA 1 | 2,504 | 3,014 | 3,286 | 3,947 | 4,411 | 5,514 | 6,328 | 7,072 |
| EBIT | - | - | 3,152 | 3,478 | 4,520 | - | 6,028 | 7,060 |
| Operating Margin | - | - | 29.7% | 27.4% | 30.82% | - | 31.18% | 32.31% |
| Earnings before Tax (EBT) 1 | - | 2,695 | 3,136 | 3,858 | 4,514 | 5,644 | 6,422 | 6,846 |
| Net income 1 | - | 2,150 | 2,423 | 2,998 | 3,763 | 4,571 | 5,137 | 5,324 |
| Net margin | - | 24.91% | 22.83% | 23.62% | 25.65% | 26.98% | 26.57% | 24.36% |
| EPS 2 | - | 28.20 | 31.71 | 39.26 | 49.18 | 59.90 | 64.20 | 74.00 |
| Free Cash Flow 1 | - | -320.6 | 1,953 | 2,456 | 779 | 2,128 | 3,277 | 3,982 |
| FCF margin | - | -3.71% | 18.4% | 19.35% | 5.31% | 12.57% | 16.95% | 18.22% |
| FCF Conversion (EBITDA) | - | - | 59.43% | 62.22% | 17.66% | 36.28% | 51.79% | 56.31% |
| FCF Conversion (Net income) | - | - | 80.6% | 81.9% | 20.7% | 46.55% | 63.79% | 74.81% |
| Dividend per Share 2 | - | 2.500 | 3.000 | 2.000 | 2.000 | 3.150 | 3.300 | 3.650 |
| Announcement Date | 19-05-22 | 20-06-18 | 21-05-06 | 22-05-12 | 23-05-27 | 24-05-16 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2021 Q3 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,744 | 3,004 | 3,035 | 3,262 | 3,463 | 3,590 | 3,721 | 3,893 | 3,953 | 4,111 | 4,381 | 4,462 |
| EBITDA 1 | 897.5 | 926.1 | 1,012 | - | 1,022 | 1,056 | 1,094 | 1,239 | 1,266 | 1,234 | 1,395 | 2,986 |
| EBIT | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 644.6 | 708.5 | 749.8 | - | 849.9 | 916.7 | 974.8 | 1,021 | 1,034 | 970 | 1,179 | 1,232 |
| Net margin | 23.49% | 23.58% | 24.7% | - | 24.54% | 25.53% | 26.2% | 26.23% | 26.16% | 23.6% | 26.91% | 27.62% |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 21-02-04 | 21-08-05 | 21-11-02 | 22-02-03 | 22-08-05 | 22-11-12 | 23-02-11 | 23-05-27 | 23-08-07 | - | - | - |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -321 | 1,953 | 2,456 | 779 | 2,128 | 3,277 | 3,983 |
| ROE (net income / shareholders' equity) | 35.4% | 27.2% | 22.7% | 22.5% | 22.4% | 20.9% | 18.6% | 16.2% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 83.30 | 124.0 | 157.0 | 196.0 | 248.0 | 303.0 | 406.0 | 456.0 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | - | 767 | 733 | 912 | 1,938 | 1,304 | 1,000 | 1,000 |
| Capex / Sales | - | 8.89% | 6.91% | 7.18% | 13.21% | 7.71% | 5.17% | 4.58% |
| Announcement Date | 19-05-22 | 20-06-18 | 21-05-06 | 22-05-12 | 23-05-27 | 24-05-16 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,338
INR
Average target price
1,579
INR
Spread / Average Target
+17.99%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +21.63% | 44.11B | |
| +23.03% | 22.71B | |
| +18.22% | 15.15B | |
| +12.66% | 13.56B | |
| +60.18% | 12.7B | |
| -10.02% | 6.84B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +12.92% | 5.63B |
- Stock Market
- Equities
- CAPLIPOINT Stock
- CAPLIPOINT Stock
- Financials Caplin Point Laboratories Limited